Report was overpositive about their benefitsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2917 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2917
- Rafael S Scheffel, endocrinologist,
- Beatriz D Schaan, postgraduate student
- 1Hospital de Clínicas de Porto Alegre, Serviço de Medicina Interna, Porto Alegre, RS, Brazil
Although Karagiannis and colleagues’ study has methodological strengths worth citing, we disagree with some of the conclusions.
In the evaluation of the prespecified primary endpoint (difference in glycated haemoglobin (HbA1c); fig 2), the performance of the dipeptidyl peptidase-4 (DPP-4) inhibitors was far below that of the drugs used as active comparators …